Where does EYE Tech Care rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), EYE Tech Care ranks #35,267 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does EYE Tech Care hold?

EYE Tech Care holds 7 US utility patents granted between 2016 and 2024, spanning 4 technology areas.

What is EYE Tech Care's Innovation Score?

EYE Tech Care has an Innovation Score of 25.2 out of 100 (17th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does EYE Tech Care focus on?

EYE Tech Care's top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 7 patents, ranking #515 of 1,943 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is EYE Tech Care's patent grant rate increasing or decreasing?

EYE Tech Care's recent grant velocity is -25% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for EYE Tech Care's patents?

EYE Tech Care's patents average 12.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the EYE Tech Care patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

EYE Tech Care

USPTO PatentsView assignee record - 7 granted patents across 4 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, EYE ranks #35,267 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 4 technology areas.

#35,267
of 49,997 US assignees by volume: 17th percentile
by Innovation Score (25.2/100): 12.7
avg claims per patent: -25%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R35267 · Foreign Corporation #35,267 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 7 grants
MID-PACK #35,267/49,997
PHOTO-FINISH Eagle Actuator…
CPC-NARROW A61N · 4 areas
INNOV-THIN 25.2/100
CLAIMS-RICH 12.7 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -25% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Eagle Actuator Components GmbH & Co. KG (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How EYE’s 25.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (29%) Velocity 3.3 pts (13%) Breadth 7.1 pts (28%) Claim depth 7.6 pts (30%)

Qualcomm Incorporated · highest

85
EYE Tech Care · this assignee

25
3D Lighting… · lowest

7

What this shows EYE's Innovation Score is 25.2/100 (17th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for EYE?

Each dot is one of EYE’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). EYE’s own 12.7 claims/patent is ABOVE the 10.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

EYE vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where EYE's grants concentrate

EYE Tech Care is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2016 (3 grants) versus a trough of 1 in 2018. By volume, EYE sits between Evoko Unlimited AB and Eagle Point Medical LLC.

EYE's three-year grant acceleration

EYE Tech Care shows 1 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Evoko Unlimited AB

7
Evolv

7
Exergy Power Syst…

7
Exquadrum

7
Eyegene

7
Eagle Actuator Co…

7
Eagle Industries…

7
Eagle Point Medic…

7
EYE Tech Care ◀

7

What this shows EYE holds 7 patents at rank #35,179, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near EYE

By rank, the assignees closest to #35,179 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in EYE's primary technology class.

EYE's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

25 17th percentile higher than 17% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

EYE Tech Care patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	3	42.9%
2018	1	14.3%
2020	1	14.3%
2021	1	14.3%
2024	1	14.3%

Which technologies does EYE Tech Care patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 7

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 7

A61B - DIAGNOSIS; SURGERY; Identification 3

B06B - Methods OR Apparatus FOR Generating OR Transmitting Mechanical Vibrations OF Infrasonic, Sonic, OR Ultrasonic Frequency, ; e.g.; FOR Performing Mechanical Work IN General 1

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

EYE Tech Care's patent record in context - here's where to go next.

EYE Tech Care's lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 100% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #35,267 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare EYE Tech Care against Evoko Unlimited AB, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 25.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.